This study compares the effects of digoxin, placebo and ibopamine (SB-7505), the orally active 3,4-diisobutyryl ester of N-methyl-dopamine, on exercise tolerance and cardiac rhythm of 14 patients whose left ventricular heart failure (end-diastolic pressure, 26.3 +/- 5.9 mmHg; ejection fraction, 0.42 +/- 0.10%) depended on a previous myocardial infarction. Patients were admitted to the study while on chronic oral digoxin treatment (serum levels between 1.1 and 1.9 ng/ml). Placebo instead of digoxin was given for the following month. Thereafter ibopamine 50 mg t.i.d. for one month was given. A sequence of one-month treatments with digoxin, placebo and ibopamine was repeated, then ibopamine was administered continuously for the next two months. The concurrent treatment (diuretics in all patients, nitroderivates in twelve, calcium antagonists in two) remained unchanged during the observation period. Symptoms-limited exercise tests and 24-h Holter recordings were obtained at admission, at the end of each one-month treatment and at the end of the observation period. Two patients developed unstable angina without increase of serum creatine phosphokinase while on ibopamine and were withdrawn. Out of the 12 patients that concluded the trial, one required supplementary doses of diuretic at the end of the second period on placebo. The results obtained during the trial suggest that: a) therapeutic plasma levels of digoxin have no deleterious effect on cardiac rhythm nor significantly increase exercise tolerance as compared with placebo; b) diuretics and nitrates appear to sustain the clinical stability of these patients as a group.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source

Publication Analysis

Top Keywords

digoxin placebo
12
placebo ibopamine
12
exercise tolerance
12
cardiac rhythm
12
effects digoxin
8
tolerance cardiac
8
rhythm patients
8
left ventricular
8
observation period
8
patients
7

Similar Publications

Article Synopsis
  • - The study examined how the Na,K-ATPase inhibitor digoxin affects muscle content, potassium levels, and fatigue during intense exercise in healthy adults, using a double-blind crossover design with a placebo.
  • - Results showed that while muscle Na,K-ATPase binding increased with digoxin treatment, muscle isoform levels did not change, suggesting a potential adaptation mechanism to maintain Na,K-ATPase function despite the drug's effects.
  • - Exercise produced significant shifts in potassium levels, with digoxin leading to earlier fatigue and altered potassium responses compared to the placebo, highlighting digoxin's impact on muscle performance during high-intensity activities.
View Article and Find Full Text PDF

Background: Inflammation and angiogenesis are two main mechanisms that act as mutual pathways in rheumatoid arthritis (RA). This work aimed to study the efficacy of digoxin as an adjunct therapy to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in active RA patients.

Methods: In a randomized, double-blinded, placebo-controlled study, 60 adult patients with active RA received a placebo or digoxin (0.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiogenic shock (CS) poses significant health risks, necessitating effective interventions to maintain blood pressure and tissue perfusion, while current treatments, like inotropes, can lead to serious side effects.
  • The SEISMiC study aims to evaluate the safety and effectiveness of istaroxime, a new drug that may improve blood flow without overstimulating adrenergic receptors, in patients at risk for CS.
  • This multinational, double-blind study involves patients with severe heart failure and aims to measure the drug's impact on blood pressure and other cardiac metrics over a 60-hour period, aiming to clarify istaroxime's potential benefits in managing pre-CS conditions.
View Article and Find Full Text PDF

In muscle, digoxin inhibits Na,K-ATPase (NKA) whereas acute exercise can increase NKA gene expression, consistent with training-induced increased NKA content. We investigated whether oral digoxin increased NKA isoform mRNA expression (qPCR) in muscle at rest, during and post-exercise in 10 healthy adults, who received digoxin (DIG, 0.25 mg per day) or placebo (CON) for 14 days, in a randomised, double-blind and cross-over design.

View Article and Find Full Text PDF

Aims: Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of digoxin used in that trial (and other studies) may have been too high. The DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands) trial will examine the efficacy and safety of low-dose digoxin in HF patients with reduced or mildly reduced left ventricular ejection fraction (LVEF) with a background of contemporary HF treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!